Zurich Cantonal Bank
TRDA icon

Zurich Cantonal Bank’s Entrada Therapeutics TRDA Stock Holding History

Zurich Cantonal Bank’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.8K Buy
2,688
+1,271
+90% +$12.2K ﹤0.01% 2480
2026
Q1 		$17.9K Buy
1,417
+985
+228% +$11.3K ﹤0.01% 2461
2025
Q4 		$4.44K Hold
432
– – ﹤0.01% 2503
2025
Q3 		$2.51K Sell
432
-314
-42% -$1.84K ﹤0.01% 2524
2025
Q2 		$5.01K Hold
746
– – ﹤0.01% 2537
2025
Q1 		$6.74K Buy
+746
New +$9.3K ﹤0.01% 2606

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Zurich Cantonal Bank's TRDA Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Entrada Therapeutics (TRDA) stake by 90% in Q2 2026, buying an estimated $12.2K and bringing the position to 2,688 shares worth $19.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2480.

Zurich Cantonal Bank first reported a position in TRDA in Q1 2025 and has held it in 6 quarters since. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Zurich Cantonal Bank held 2,688 shares of Entrada Therapeutics worth $19.8K as of Q2 2026.
  • Zurich Cantonal Bank bought 1,271 Entrada Therapeutics shares in Q2 2026, an estimated $12.2K.
  • Entrada Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2480 holding.
  • Zurich Cantonal Bank first reported a position in Entrada Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.